Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

@article{Bandelow2007PregabalinFT,
  title={Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention},
  author={Borwin Bandelow and Dirk Wedekind and Teresa Le{\'o}n},
  journal={Expert Review of Neurotherapeutics},
  year={2007},
  volume={7},
  pages={769 - 781}
}
Pregabalin is the first anxiolytic pharmacologic alternative for the treatment of generalized anxiety disorder (GAD) to be introduced in more than 10 years. GAD is a significant psychiatric condition with lifetime prevalence rates ranging between 5.7 and 6.4%. It causes significant impairment in quality of life and functional abilities equivalent to those associated with major depression. Randomized, controlled trials confirm that pregabalin is superior to placebo and comparable with lorazepam… Expand
Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder
TLDR
Pregabalin (Lyrica®), a well established anxiolytic agent, has been approved in the EU for the treatment of generalized anxiety disorder (GAD) in adults and is considered a first-line agent for the long-term treatment of GAD by the World Federation of Societies of Biological Psychiatry. Expand
Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature
TLDR
A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium. Expand
Pregabalin versus sertraline in generalized anxiety disorder. An open label study.
TLDR
This investigation showed that pregabalin, an atypic anxiolytic is efficient and well tolerable in treatment of GAD and showed good results in treating symptoms of Generalized Anxious Disorder. Expand
Generalized Anxiety Disorder in Adults: Focus on Pregabalin
TLDR
Pregabalin is a novel structural analogue of the inhibitory neurotransmitter GABA, acting to reduce calcium ion flow through the α2δ subunit of pre-synaptic voltage-dependent calcium channels, which has low abuse potential. Expand
A Meta-Analysis of the Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder
  • M. Boschen
  • Psychology, Medicine
  • Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2011
TLDR
Pregabalin is an efficacious therapy for GAD, although effect sizes are smaller than those from earlier studies. Expand
Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder
TLDR
Pregabalin is an alternative compound to SSRIs and SNRIs for the first-line treatment of generalized anxiety disorder (GAD) and its favorable pharmacokinetic properties are all favorable for the treatment of GAD patients, including those with comorbid depressive symptoms or medical conditions. Expand
Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin
TLDR
Evidence from available randomized placebo-controlled as well as head-to-head clinical trials with other drugs regarding its efficacy and safety in the GAD treatment is evaluated. Expand
Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence
TLDR
Monotherapy with pregabalin, within the dosage range of 150 – 600 mg/d, is a promising “novel” option for the safe and efficacious relapse prevention of both AD and BD, however, its efficacy in the acute treatment of AD withdrawal syndrome is still controversial. Expand
Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study.
TLDR
This study does not support the usefulness of adding pregabalin in patients with GAD and UMD and with an early nonresponse to escitalopram. Expand
Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis
TLDR
Patient-level data were pooled from nine phase II and III randomized, double-blind, short-term, placebo-controlled trials of pregabalin for the treatment of GAD to determine those predictive of clinical improvement at endpoint. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Pregabalin for the treatment of generalised anxiety disorder
TLDR
Pregabalin was effective in more or less severe G AD, on psychic and somatic symptoms of GAD, and in treating the subsyndromal depressive symptoms in the elderly and the effect on cognitive function was minimal and notably less than that observed with benzodiazepines. Expand
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
TLDR
Pregabalin was safe, well tolerated, and rapidly efficacious across the physical-somatic as well as the emotional symptoms of GAD in the majority of patients studied in primary care and psychiatric settings. Expand
Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
TLDR
Pregabalin is an effective, rapidly acting, and safe treatment for generalized anxiety disorder in short-term treatment and does not appear to have the withdrawal symptoms associated with the benzodiazepines. Expand
Pregabalin: in the treatment of generalised anxiety disorder.
TLDR
Oral pregabalin, typically at dosages of 300-600 mg/day, was superior to placebo and similar to lorazepam, alprazolam and venlafaxine in improving anxiety and depressive symptoms in patients with moderate-to-severe generalised anxiety disorder (GAD). Expand
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
TLDR
Pregabalin was significantly more efficacious than placebo for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients. Expand
Evidence-based pharmacotherapy of Generalized Anxiety Disorder.
TLDR
Due to their efficacy in GAD and comorbid anxiety and depressive disorders, their tolerability and safety, certain selective serotonin re-uptake inhibitors (escitalopram, paroxetine, sertraline) should be considered the first-line treatment for most patients, although the serotonin-noradrenaline re-ptake inhibitor venlafaxine is a reasonable alternative. Expand
Escitalopram in the treatment of generalized anxiety disorder
TLDR
Escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine. Expand
Long-term efficacy of pregabalin in generalized anxiety disorder
TLDR
The study indicates that pregabalin is an effective treatment for the prevention of relapse in patients with GAD. Expand
Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder
TLDR
Clinically important differences were noted between drugs in the onset of effect, with alprazolam producing rapid and sustained improvement within the first week of treatment and buspirone producing more gradual, continuous improvement throughout the study. Expand
Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.
TLDR
The results of the study need replication, but suggest a potentially important role for antidepressants, particularly imipramine, in patients suffering from GAD. Expand
...
1
2
3
4
5
...